Listen to this article on the DDW Podcast: Synthetic biology is increasingly important to drug discovery and development. Reece Armstrong examines recent activity within the sector and highlights some of the key advancements and innovation. Partnerships Earlier this year cell-engineering company MaxCyte signed a strategic platform license (SPL) with biotechnology company Catamaran Bio. The agreement will […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!